Emate

Emate

SCHEMBL6370815

C[C@]12CCC3c4ccc(OS(N)(=O)=O)cc4CCC3C1CCC2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 16/20 1.00
CA2 P00918 4/20 1.00
CA1 P00915 3/20 1.00
CA9 Q16790 3/20 1.00
ESR1 P03372 2/20 1.00
ESR2 Q92731 2/20 1.00
CA4 P22748 1/20 1.00
CA6 P23280 1/20 1.00
ABCC4 O15439 1/20 0.80
CYP2C9 P11712 1/20 0.80
ABCC1 P33527 1/20 0.80
SLCO1B1 Q9Y6L6 1/20 0.80
KDM4E B2RXH2 1/20 0.80
LMNA P02545 2/20 0.76
MAPT P10636 2/20 0.76
HSD17B1 P14061 2/20 0.76
RECQL P46063 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
CYP3A4 P08684 2/20 0.73
CA5A P35218 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Emate SCHEMBL305660 1.00 STS (1.00) STSCA2CA1CA9ESR1
Emate SCHEMBL14548146 1.00 STS (1.00) STSCA2CA1CA9ESR1
Emate SCHEMBL29406834 1.00 STS (1.00) STSCA2CA1CA9ESR1
Emate SCHEMBL10062721 1.00 STS (1.00) STSCA2CA1CA9ESR1
SCHEMBL21067318 0.91 STS (0.84) STSCA2CA1CA9ESR1
Emate SCHEMBL7164522 0.91 STS (0.86) STSCA2CA1CA9ESR1
SCHEMBL17531381 0.90 STS (0.82) STSCA2CA1CA9ESR1
SCHEMBL8034430 0.90 STS (0.82) STSCA2CA1CA9ESR1
Estrone Sulfuric Acid SCHEMBL2296097 0.89 KDM4E (0.96) STSCA2CA1CA9ESR1
Estrone Sulfuric Acid SCHEMBL22846 0.89 STS (1.00) STSCA2CA1CA9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841548-B2 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives SCHERING AG (DE) 2005-01-11 US claimed
EP-0775155-B1 ESTRA-1,3,5(10)-TRIENE DERIVATIVES, METHODS OF PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING AG (DE) 2004-05-06 EP claimed
US-20020061868-A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives STERIX LIMITED (GB) 2002-05-23 US claimed
CN-121652368-A Water-based polyurethane-polyurea emulsion and preparation method thereof 广东普赛达材料科技股份有限公司 2026-03-13 CN disclosed
US-20200163913-A1 CA-4 Antitumour Drug, Synthesis Method and Use Thereof SHANGHAI HUALI BIOMEDICAL CO., LTD. (CN) 2020-05-28 US disclosed
WO-2019020016-A1 CA-4 ANTITUMOUR DRUG, SYNTHESIS METHOD AND USE THEREOF 上海华理生物医药股份有限公司 2019-01-31 WO disclosed
EP-2484351-B1 Use of steroid sulfatase inhibitors for the treatment of preterm labor PREGLEM SA (CH) 2016-02-24 EP disclosed
US-20150065470-A1 Steroid Sulfatase Inhibitor Regimen for the Treatment of Endometriosis PREGLEM SA (CH) 2015-03-05 US disclosed
US-20150065470-A1 Steroid Sulfatase Inhibitor Regimen for the Treatment of Endometriosis PREGLEM SA (CH) 2015-03-05 US disclosed
WO-2013150471-A1 STEROID SULFATASE INHIBITOR REGIMEN FOR THE TREATMENT OF ENDOMETRIOSIS PREGLEM SA (CH) 2013-10-10 WO disclosed
EP-2647378-A1 Steroid sulfatase inhibitor regimen for the treatment of endometriosis PregLem S.A. (CH) 2013-10-09 EP disclosed
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2007-05-17 US disclosed
US-20070105886-A1 Steroidal compounds for inhibiting steroid sulphatase RICHTER GEDEON NYRT. (HU) 2007-05-10 US disclosed
US-20070021492-A1 e.g. sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-yl-1,1-dioxide ester; estrogen-dependent diseases LABORATOIRE THERAMEX (MC) 2007-01-25 US disclosed
US-20070021492-A1 e.g. sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-yl-1,1-dioxide ester; estrogen-dependent diseases LABORATOIRE THERAMEX (MC) 2007-01-25 US disclosed
US-6841548-B2 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives SCHERING AG (DE) 2005-01-11 US disclosed
EP-0775156-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5(10)-TRIENE DERIVATIVES JENAPHARM GMBH (DE) 2003-09-03 EP disclosed
US-6569844-B1 Hormonal contraception and hormon replacement therapy with low hepatic estrogenity JENAPHARM GMBH & CO., KG (DE) 2003-05-27 US disclosed
US-20020061868-A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives STERIX LIMITED (GB) 2002-05-23 US disclosed
US-6080735-A SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES JENAPHARM GMBH & CO. KG (DE) 2000-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061868-A1 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives ESRRA, ESR2, CYP19A1 STS 124/4885CA2 4144/4885CA1 3531/4885
US-20070021492-A1 e.g. sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-yl-1,1-dioxide ester; estrogen-dependent diseases SULT1E1, SULT1A1, SULT2A1 STS 7/4885CA2 623/4885CA1 267/4885
US-20150065470-A1 Steroid Sulfatase Inhibitor Regimen for the Treatment of Endometriosis SULT2A1, SULT1E1, STS STS 3/4885CA2 988/4885CA1 685/4885
US-20070105886-A1 Steroidal compounds for inhibiting steroid sulphatase STS, NR5A1, CYP21A2 STS 1/4885CA2 1367/4885CA1 630/4885
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them H1-0, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 STS 4396/4885CA2 2378/4885CA1 4252/4885
US-20200163913-A1 CA-4 Antitumour Drug, Synthesis Method and Use Thereof CA4, CA14, CA6 STS 105/4885CA2 5/4885CA1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.